Table 1_Communal and agentic teacher behavior in teacher-child dyads. A new self-report scale based on a circumplex approach.docx by Madeleine Kreutzmann (20296713)

“…Introduction<p>The goal of this study was to develop a self-report scale measuring the teacher’s interpersonal behavior in teacher-child dyads in elementary schools and to provide evidence of the scale’s validity. …”

Data Sheet 1_Renewable energy consumption optimization allocation strategy for a regional microgrid based on a shared energy storage mechanism.zip by Hongde Ma (20137539)

“…This indicates that the proposed method for constructing a bilayer optimization configuration can effectively consider the economic consumption of new energy and significantly improve the economic operation of shared energy storage stations and regional microgrids.…”

Changes in the neutrophil count. by Lu Yang (30847)

“…</p><p>Methods</p><p>This is a single-center, prospective, randomized controlled study conducted from June 1, 2021, to October 31, 2022 on patients diagnosed with locally advanced NPC. …”

Changes in the platelet count. by Lu Yang (30847)

“…</p><p>Methods</p><p>This is a single-center, prospective, randomized controlled study conducted from June 1, 2021, to October 31, 2022 on patients diagnosed with locally advanced NPC. …”

Changes in the white blood cell count. by Lu Yang (30847)

“…</p><p>Methods</p><p>This is a single-center, prospective, randomized controlled study conducted from June 1, 2021, to October 31, 2022 on patients diagnosed with locally advanced NPC. …”

Changes in the hemoglobin. by Lu Yang (30847)

“…</p><p>Methods</p><p>This is a single-center, prospective, randomized controlled study conducted from June 1, 2021, to October 31, 2022 on patients diagnosed with locally advanced NPC. …”

WBC and ANC on day 7 post-chemotherapy. by Lu Yang (30847)

“…</p><p>Methods</p><p>This is a single-center, prospective, randomized controlled study conducted from June 1, 2021, to October 31, 2022 on patients diagnosed with locally advanced NPC. …”

General clinical data of 88 patients with NPC. by Lu Yang (30847)

“…</p><p>Methods</p><p>This is a single-center, prospective, randomized controlled study conducted from June 1, 2021, to October 31, 2022 on patients diagnosed with locally advanced NPC. …”

CONSORT participant flow diagram. by Lu Yang (30847)

“…</p><p>Methods</p><p>This is a single-center, prospective, randomized controlled study conducted from June 1, 2021, to October 31, 2022 on patients diagnosed with locally advanced NPC. …”

S4 File - by Lu Yang (30847)

“…</p><p>Methods</p><p>This is a single-center, prospective, randomized controlled study conducted from June 1, 2021, to October 31, 2022 on patients diagnosed with locally advanced NPC. …”

Data Sheet 6_A genome-wide shRNA screen uncovers a novel potential ligand for NK cell activating receptors.pdf by Paolo Romania (399007)

“…PLAC1 and DSG2 expression in healthy tissues and NK cells was obtained from the HPA database and a GEO dataset.</p>Results<p>We identified ten candidate genes whose downregulation in K562 cells decreased NK cell-mediated cytotoxicity to levels comparable to silencing the MICA gene. …”

Data Sheet 4_A genome-wide shRNA screen uncovers a novel potential ligand for NK cell activating receptors.pdf by Paolo Romania (399007)

“…PLAC1 and DSG2 expression in healthy tissues and NK cells was obtained from the HPA database and a GEO dataset.</p>Results<p>We identified ten candidate genes whose downregulation in K562 cells decreased NK cell-mediated cytotoxicity to levels comparable to silencing the MICA gene. …”

Data Sheet 3_A genome-wide shRNA screen uncovers a novel potential ligand for NK cell activating receptors.pdf by Paolo Romania (399007)

“…PLAC1 and DSG2 expression in healthy tissues and NK cells was obtained from the HPA database and a GEO dataset.</p>Results<p>We identified ten candidate genes whose downregulation in K562 cells decreased NK cell-mediated cytotoxicity to levels comparable to silencing the MICA gene. …”

Data Sheet 5_A genome-wide shRNA screen uncovers a novel potential ligand for NK cell activating receptors.pdf by Paolo Romania (399007)

“…PLAC1 and DSG2 expression in healthy tissues and NK cells was obtained from the HPA database and a GEO dataset.</p>Results<p>We identified ten candidate genes whose downregulation in K562 cells decreased NK cell-mediated cytotoxicity to levels comparable to silencing the MICA gene. …”

Sox2 is upstream of <i>Atoh1</i> and <i>Huwe1</i> in embryonic development and <i>Huwe1</i> knockdown results in hair cell generation from dividing supporting cells. by Yen-Fu Cheng (5819855)

Certainty of affect predicted by valence and low, medium, and high trait emotional intelligence Predicted certainty of knowing how you feel in a trial, as predicted by the subject’... by Anthony G. Vaccaro (5964368)

Discovery of Tamsulosin Derivatives with Shifted Selectivity from the α₁‑Adrenergic Receptor to ANO1 as Potent Antiosteoporotic Agents by Chaoquan Tian (21009122)

“…The potency of compound <b>10</b> against ANO1 was comparable to that of <b>Tam</b> (IC₅₀: 4.57 vs 7.22 μM), but its selectivity over α₁-AR was significantly improved. Compared with <b>Tam</b>, the potency of compound <b>10</b> against α_1A-, α_1B-, and α_1D-AR decreased by 118-fold, 642-fold, and 10,000-fold, respectively. …”

Discovery of Tamsulosin Derivatives with Shifted Selectivity from the α₁‑Adrenergic Receptor to ANO1 as Potent Antiosteoporotic Agents by Chaoquan Tian (21009122)

“…The potency of compound <b>10</b> against ANO1 was comparable to that of <b>Tam</b> (IC₅₀: 4.57 vs 7.22 μM), but its selectivity over α₁-AR was significantly improved. Compared with <b>Tam</b>, the potency of compound <b>10</b> against α_1A-, α_1B-, and α_1D-AR decreased by 118-fold, 642-fold, and 10,000-fold, respectively. …”

Discovery of Tamsulosin Derivatives with Shifted Selectivity from the α₁‑Adrenergic Receptor to ANO1 as Potent Antiosteoporotic Agents by Chaoquan Tian (21009122)

“…The potency of compound <b>10</b> against ANO1 was comparable to that of <b>Tam</b> (IC₅₀: 4.57 vs 7.22 μM), but its selectivity over α₁-AR was significantly improved. Compared with <b>Tam</b>, the potency of compound <b>10</b> against α_1A-, α_1B-, and α_1D-AR decreased by 118-fold, 642-fold, and 10,000-fold, respectively. …”

Data Sheet 1_Effect of a high dose atorvastatin as adjuvant therapy to mesalamine in attenuating inflammation and symptoms in patients with ulcerative colitis: a randomized control... by Sumaiah J. Alarfaj (12889115)

“…</p>Results<p>Compared to the placebo group (n = 24), the atorvastatin group (n = 23) exhibited a significant decrease in the level of IL-6 (p = 0.001), S1P (p = 0.0001), TNF-α (p = 0.003), NO (p = 0.0001), CRP (p = 0.015), ESR (p = 0.012), PMS (p = 0.013), and fecal calprotectin (p = 0.0003), and improved SF-36 (p = 0.006). …”